Is switching from Levemir (detemir) 19 units every night to Lantus (glargine) 19 units every night equivalent for an adult patient with diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Converting Levemir 19 Units to Lantus 19 Units

A 1:1 unit conversion from Levemir 19 units nightly to Lantus 19 units nightly is appropriate for most patients, though a 10-20% dose reduction should be considered for high-risk individuals. 1

Standard Conversion Protocol

For patients on once-daily Levemir, convert unit-for-unit to once-daily Lantus. 1 The American Diabetes Association supports this 1:1 conversion approach, as both insulin detemir (Levemir) and insulin glargine (Lantus) are long-acting basal insulin analogues with similar glycemic efficacy. 2

  • Clinical trial data demonstrates equivalent HbA1c lowering between glargine and detemir in both type 1 and type 2 diabetes. 3, 4
  • Both insulins achieve similar fasting plasma glucose control when dosed appropriately. 3

Critical Consideration: Twice-Daily Levemir Patients

If this patient was previously on twice-daily Levemir, sum both daily doses and reduce by 10-20% when converting to once-daily Lantus. 1 This reduction accounts for the pharmacokinetic differences between the two insulins—many patients require twice-daily detemir dosing to achieve 24-hour coverage, whereas glargine typically provides full 24-hour coverage with once-daily administration. 5, 6

High-Risk Patient Modifications

Reduce the converted dose by 10-20% for the following populations: 1

  • Elderly patients (>65 years) 1
  • Patients with renal impairment 1
  • History of severe hypoglycemia 1
  • Poor oral intake or acute illness 1

The rationale for dose reduction in high-risk patients is the lower risk of severe hypoglycemia with glargine compared to NPH insulin (OR 0.65), though direct comparison data between detemir and glargine shows similar hypoglycemia rates. 2

Post-Conversion Monitoring Requirements

Daily fasting blood glucose monitoring is essential during the first 1-2 weeks after conversion. 1 Adjust the dose every 3 days based on fasting glucose values, targeting 80-130 mg/dL. 1

Dose adjustment algorithm: 1

  • If fasting glucose is 140-179 mg/dL: increase by 2 units every 3 days
  • If fasting glucose is ≥180 mg/dL: increase by 4 units every 3 days
  • If hypoglycemia occurs: reduce dose immediately by 10-20% and reassess

Administration Timing

Administer Lantus at the same time each day, typically with the evening meal or at bedtime. 1 This maintains consistency with the previous Levemir bedtime dosing schedule.

Common Pitfalls to Avoid

Do not dilute or mix Lantus with any other insulin or solution due to its low pH diluent. 1, 7 This is a critical safety consideration emphasized by the American Association of Clinical Endocrinologists. 1

Do not assume the conversion will be perfect—individual patient response varies. 4 While meta-analyses show no clinically significant differences in efficacy between detemir and glargine, some patients may require dose adjustments based on their glucose response. 4

Continue metformin and other non-insulin diabetes medications unless contraindicated. 2 The basal insulin conversion does not necessitate changes to the foundation diabetes therapy.

References

Guideline

Insulin Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin detemir versus insulin glargine for type 2 diabetes mellitus.

The Cochrane database of systematic reviews, 2011

Research

[Insulin analogues: place of detemir (levemir)].

Revue medicale de Bruxelles, 2006

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Should Lantus (insulin glargine) be refrigerated?
What is a suitable substitute for Lantus (insulin glargine)?
What is an example of long-acting insulin?
What is the recommended starting dose and brand of insulin (e.g. Lantus (insulin glargine), Levemir (insulin detemir), Humalog (insulin lispro), Novolog (insulin aspart)) for initiating insulin therapy?
What is the generic name of Lantus (insulin glargine)?
What medications should be given to a patient with shortness of breath (SOB), bilateral crepitations in the basal region, and X-ray findings suggestive of pulmonary edema ('bat winging') with a diagnosis of lower respiratory tract infection (LRTI), who is on oxygen support and awaiting an echocardiogram?
What are the recommended methods for sending a blood sample from a patient undergoing dialysis to minimize infection and contamination risk?
What is the clinical significance and management of a high Frax (Fracture Risk Assessment) score in postmenopausal women and older adults with increased risk of fracture?
What is the preferred treatment between sildenafil (Sildenafil) and tadalafil (Tadalafil) for a patient with systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH)?
Should I initiate SGLT2 (Sodium-Glucose Linked Transporter 2) inhibitors, beta blockers, and Angiotensin II Receptor Blockers (ArBs) in a patient with heart failure with reduced ejection fraction (HFrEF), pulmonary edema, and a lower respiratory tract infection (LRTI)?
How does a patient with abdominal pain, diarrhea, and weight loss present with symptoms suggestive of inflammatory bowel disease, such as ulcerative colitis or Crohn's disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.